LeonaBio (LONA) Common Equity (2019 - 2026)

LeonaBio (LONA) has 8 years of Common Equity data on file, last reported at $49.3 million in Q1 2026.

• On a quarterly basis, Common Equity rose 32.07% year-over-year to $49.3 million in Q1 2026; TTM through Mar 2026 was $49.3 million, a 32.07% increase from a year earlier, with the FY2025 full-year figure at $27.8 million, down 38.03% from the prior year.
• Common Equity for Q1 2026 stood at $49.3 million, up from $27.8 million in the prior quarter.
• Over the last five years, Common Equity for LONA reached as high as $302.0 million in Q1 2022 and fell as low as $26.8 million in Q3 2025.
• Historically, Common Equity has averaged $131.0 million across 5 years, with a median of $106.7 million in 2024.
• Across the five-year window, Common Equity tumbled 65.56% in 2024 and surged 32.07% in 2026, its largest moves.
• Year by year, Common Equity stood at $235.1 million in 2022, then plunged by 44.63% to $130.2 million in 2023, then tumbled by 65.56% to $44.8 million in 2024, then plunged by 38.03% to $27.8 million in 2025, then soared by 77.41% to $49.3 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $49.3 million in Q1 2026, $27.8 million in Q4 2025, and $26.8 million in Q3 2025.